Cargando…
Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness
Psoriasis is not optimally controlled in spite of newly developed treatments, possibly due to the difficulty of objectively quantifying the disease’s severity, considering the limitations of the clinical scores used in clinical practice. A major challenge addresses difficult-to-treat areas, especial...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785802/ https://www.ncbi.nlm.nih.gov/pubmed/36556415 http://dx.doi.org/10.3390/life12122050 |
_version_ | 1784858137393627136 |
---|---|
author | Nicolescu, Alin Codrut Ionescu, Marius-Anton Constantin, Maria Magdalena Ancuta, Ioan Ionescu, Sinziana Niculet, Elena Tatu, Alin Laurentiu Zirpel, Henner Thaçi, Diamant |
author_facet | Nicolescu, Alin Codrut Ionescu, Marius-Anton Constantin, Maria Magdalena Ancuta, Ioan Ionescu, Sinziana Niculet, Elena Tatu, Alin Laurentiu Zirpel, Henner Thaçi, Diamant |
author_sort | Nicolescu, Alin Codrut |
collection | PubMed |
description | Psoriasis is not optimally controlled in spite of newly developed treatments, possibly due to the difficulty of objectively quantifying the disease’s severity, considering the limitations of the clinical scores used in clinical practice. A major challenge addresses difficult-to-treat areas, especially in the absence of significant body surface involvement. It is controversial whether the severity evaluation of patients with several affected areas (having at least one difficult-to-treat area) should be done differently from current methods. Scores used for special areas (PSSI, NAPSI and ESIF) allow an accurate assessment of disease severity in difficult-to-treat areas, but the issue of whether to integrate these scores into PASI, BSA or DLQI remains. The review’s purpose resides in providing an overview of the main current issues in determining psoriasis severity in patients with psoriasis in difficult-to-treat areas and suggesting possible solutions for the optimal integration of the area assessment in current scores: severity can be either established according to the highest calculated score (PASI or PSSI or NAPSI or ESIF) or by adding a correction factor in the calculation of PASI for special areas. |
format | Online Article Text |
id | pubmed-9785802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97858022022-12-24 Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness Nicolescu, Alin Codrut Ionescu, Marius-Anton Constantin, Maria Magdalena Ancuta, Ioan Ionescu, Sinziana Niculet, Elena Tatu, Alin Laurentiu Zirpel, Henner Thaçi, Diamant Life (Basel) Review Psoriasis is not optimally controlled in spite of newly developed treatments, possibly due to the difficulty of objectively quantifying the disease’s severity, considering the limitations of the clinical scores used in clinical practice. A major challenge addresses difficult-to-treat areas, especially in the absence of significant body surface involvement. It is controversial whether the severity evaluation of patients with several affected areas (having at least one difficult-to-treat area) should be done differently from current methods. Scores used for special areas (PSSI, NAPSI and ESIF) allow an accurate assessment of disease severity in difficult-to-treat areas, but the issue of whether to integrate these scores into PASI, BSA or DLQI remains. The review’s purpose resides in providing an overview of the main current issues in determining psoriasis severity in patients with psoriasis in difficult-to-treat areas and suggesting possible solutions for the optimal integration of the area assessment in current scores: severity can be either established according to the highest calculated score (PASI or PSSI or NAPSI or ESIF) or by adding a correction factor in the calculation of PASI for special areas. MDPI 2022-12-07 /pmc/articles/PMC9785802/ /pubmed/36556415 http://dx.doi.org/10.3390/life12122050 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nicolescu, Alin Codrut Ionescu, Marius-Anton Constantin, Maria Magdalena Ancuta, Ioan Ionescu, Sinziana Niculet, Elena Tatu, Alin Laurentiu Zirpel, Henner Thaçi, Diamant Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness |
title | Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness |
title_full | Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness |
title_fullStr | Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness |
title_full_unstemmed | Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness |
title_short | Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness |
title_sort | psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785802/ https://www.ncbi.nlm.nih.gov/pubmed/36556415 http://dx.doi.org/10.3390/life12122050 |
work_keys_str_mv | AT nicolescualincodrut psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness AT ionescumariusanton psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness AT constantinmariamagdalena psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness AT ancutaioan psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness AT ionescusinziana psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness AT niculetelena psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness AT tatualinlaurentiu psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness AT zirpelhenner psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness AT thacidiamant psoriasismanagementchallengesregardingdifficulttotreatareastherapeuticdecisionandeffectiveness |